Supplementary Tables 1 - 2, Figures 1 - 2 from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
journal contribution
posted on 2023-03-31, 17:54 authored by Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer Giltnane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, Vincent A. Miller<p>PDF file - 187K, Supplementary Table 1: Detailed demographic information of all patients with metastatic breast cancer, including cohorts LM+ and EM+. Supplementary Table 2: ESR1 variant sequence data details. Abbreviations: cvg, coverage, N/A, non-applicable. Supplementary Table 3: List of genes sequenced by captured next generation sequencing. Supplementary figure 1: Genomic profiles of primary and metastatic tumors. Genomic alterations were found in 32 genes in primary and metastatic ER+ breast cancers. Genes are listed from the most frequently altered to least altered gene. Supplementary figure 2: No change in WT and mutant ER activity across a wide range of E2 doses. Luciferase activity in 293T cells after co-transfection of the ERE-TK-Luc reporter vector along with WT-ER, Y537N or D538G and E2 stimulation using doses of E2 ranging from 0.01nM to 100nM or vehicle treatment.</p>
